SCHEDULE: Janus Henderson Group Reports 14% Stake in Immix Biopharma

Janus Henderson Group Ltd. has disclosed beneficial ownership of 9,783,192 shares, representing 14.0% of Immix Biopharma, Inc.'s common stock, through various asset managers.

Summary

• Janus Henderson Group Ltd. (JHG) has filed an amendment to its Schedule 13G, reporting beneficial ownership of 9,783,192 shares of Immix Biopharma, Inc. common stock.
• This holding represents 14.0% of the class of securities.
• The shares are held through various subsidiaries and asset managers, including Janus Henderson Investors US LLC, Janus Henderson Investors UK Limited, and others.
• These asset managers exercise investment and/or voting discretion on behalf of clients, which may lead to JHG being deemed the beneficial owner.
• JHG disclaims beneficial ownership of any rights to receive dividends or proceeds from the sale of these securities held by the asset managers.
• The filing is an amendment (Amendment No. 3) and the event date requiring the filing is June 30, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, primarily reflecting a significant institutional investor's holdings and voting power without indicating new strategic shifts or performance changes.

Positives

• Significant institutional ownership by Janus Henderson Group Ltd. (14.0%) indicates confidence from a major asset manager.
• The filing clarifies the beneficial ownership structure, attributing holdings to various asset managers under JHG's umbrella.
• Shared voting power of 9,783,192 shares suggests potential influence on corporate decisions.

Negatives

• Janus Henderson Group Ltd. disclaims beneficial ownership of dividends and sale proceeds, limiting direct financial interest.
• The filing does not provide any new financial performance data or strategic updates for Immix Biopharma, Inc.

Risks

• The filing does not explicitly mention any new risks or challenges for Immix Biopharma, Inc.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Immix Biopharma, Inc.'s future performance.

Management Comments

• Janus Henderson Group Ltd. (JHG) is the ultimate parent of a number of SEC-registered investment advisers and foreign equivalents thereof.
• The Asset Managers generally exercise investment and/or voting discretion on behalf of their clients.
• The Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights.
• The Managed Portfolios have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by Janus Henderson Group Ltd. is a standard disclosure for significant institutional holdings. It indicates a substantial investment in Immix Biopharma, Inc. by a major asset manager, which can be a positive signal for other investors, but it does not provide insights into the company's operational performance or strategic direction.

Stakeholder Impact

• Shareholders: The significant stake held by Janus Henderson Group Ltd. may provide a degree of stability and indicate institutional support, potentially influencing investor sentiment.
• Management: The substantial voting power held by JHG could influence corporate governance decisions and strategic direction.
• Creditors: Increased institutional ownership might be perceived as a positive sign of company stability.

Next Steps

• Janus Henderson Group Ltd. will continue to file amendments to Schedule 13G as required by regulatory authorities.
• The asset managers will continue to exercise investment and/or voting discretion on behalf of their clients.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Asset Management, Voting Power, Investment Discretion